Natera, Inc. announced the enrollment of the first patients in the HEROES clinical trial (NCT06450314), a multi-center, phase II study. This trial explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer.
The HEROES trial is supported by funding from the French Ministry of Health and sponsored by Unicancer, a leading French hospital network dedicated to cancer. Approximately 170 metastatic HER2+ breast cancer patients are expected to enroll across up to 35 sites in France.
The primary endpoint of the study is 1-year progression-free survival in the Signatera-negative cohort, with secondary endpoints including ctDNA dynamics and quality-of-life measures. This trial aims to identify patients who may safely avoid additional therapy, potentially reshaping treatment paradigms for HER2+ breast cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.